Tong Dafeng, Yuan Jie, Wang Zhaoming, Yu Enda, E Jifu
Department of Colorectal Surgery, Changhai Hospital, Navy Military Medical University Shanghai, China.
Department of Rehabilitation, Beidaihe Rehabilitation and Recuperation Center for PLA Joint Logistics Support Force Qinhuangdao, Hebei, China.
Am J Cancer Res. 2023 Jun 15;13(6):2323-2341. eCollection 2023.
Ubiquitin-specific peptidase 37 (USP37) is a novel deubiquitinating enzyme, which has been found to be involved in the progression of multiple tumors. However, its function in colorectal cancer (CRC) remains unclear. Here, we firstly proved that USP37 was up-regulated in CRC cases, and high USP37 expression predicted poor survival of CRC cases. USP37 up-regulation promoted the proliferation, cell cycle progression, apoptosis inhibition, migration, invasion, epithelial mesenchymal transition (EMT) and stemness of CRC cells; moreover, USP37 facilitated the angiogenesis of human umbilical vein endothelial cells (HUVECs). However, USP37 silencing showed the opposite function. experiment suggested that USP37 silencing suppressed the growth and lung metastasis of CRC in nude mice. Interestingly, we found that CTNNB1 (gene coding for β-catenin) level was positively correlated with USP37 level in CRC and USP37 silencing suppressed the expression of β-catenin in CRC cells and xenograft tumor tissues. Further mechanistic studies showed that USP37 could enhance the stability of β-catenin by inhibiting its ubiquitination. Taken together, USP37 acts as an oncogene in CRC, which promotes angiogenesis, metastasis and stemness by enhancing β-catenin stability via inhibiting its ubiquitination. USP37 may be a usefully target in CRC clinical treatment.
泛素特异性蛋白酶37(USP37)是一种新型去泛素化酶,已发现其参与多种肿瘤的进展。然而,其在结直肠癌(CRC)中的功能仍不清楚。在此,我们首先证明USP37在CRC病例中上调,且USP37高表达预示CRC病例预后不良。USP37上调促进了CRC细胞的增殖、细胞周期进程、凋亡抑制、迁移、侵袭、上皮间质转化(EMT)和干性;此外,USP37促进人脐静脉内皮细胞(HUVECs)的血管生成。然而,USP37沉默显示出相反的功能。实验表明,USP37沉默抑制了裸鼠中CRC的生长和肺转移。有趣的是,我们发现CTNNB1(编码β-连环蛋白的基因)水平在CRC中与USP37水平呈正相关,且USP37沉默抑制了CRC细胞和异种移植肿瘤组织中β-连环蛋白的表达。进一步的机制研究表明,USP37可通过抑制β-连环蛋白的泛素化来增强其稳定性。综上所述,USP37在CRC中作为癌基因发挥作用,通过抑制β-连环蛋白的泛素化增强其稳定性,从而促进血管生成、转移和干性。USP37可能是CRC临床治疗中有价值的靶点。